MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2012

Jul 3, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNTA PHARMACEUTICALS CORP (SNTA)
CIK: 0001157601
Period of Report: 2012-07-01

Reporting Person: Gollust Keith R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-07-01	Common Stock	A	7312	—	Acquired	194693	Direct
2012-07-01	Common Stock	A	3656	—	Acquired	198349	Direct
2012-07-01	Common Stock	A	1828	—	Acquired	200177	Direct
2012-07-01	Common Stock	A	914	—	Acquired	201091	Direct
2012-07-01	Common Stock	A	914	—	Acquired	202005	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-07-01	Director Stock Option (Right to Buy)	$5.47	A	10000	Acquired	2022-07-01	Common Stock (10000)	Direct
2012-07-01	Director Stock Option (Right to Buy)	$5.47	A	4500	Acquired	2022-07-01	Common Stock (4500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1827967	Indirect

Footnotes

F1: Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as a director of the Issuer on such date.

F2: Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as Chairman of the Board of Directors of the Issuer on such date.

F3: Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as Chairman of the Nominating and Governance Committee of the Board of Directors of the Issuer on such date.

F4: Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as a member of the Audit Committee of the Board of Directors of the Issuer on such date.

F5: Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as a member of the Compensation Committee of the Board of Directors of the Issuer on such date.

F6: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F7: The option vests as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as a director of the Issuer on such date.

F8: The option vests as to 25% of the shares on each of September 30, 2012, December 31, 2012, March 31, 2013 and June 30, 2013, provided the Reporting Person continues to serve as Chairman of the Board of Directors of the Issuer on such date.